Use of Dapoxetine in Premature Ejaculation Management: Review Article

Abstract

Background: Premature ejaculation (PE) isn’t life-threatening, but it has a negative influence on the lives of both the patient and their partners. Varied researches have employed different definitions of PE, which include, for example, the number of intra-vaginal thrusts and the duration of male voluntary control. Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) medication, one of many commonly prescribed for depressive symptoms. Cognitive behavioral therapy (CBT) has been widely utilised to treat PE prior to the availability of dapoxetine. Other than dapoxetine, other Off-label usage of SSRIs in the treatment of PE has increased in recent years. Objective: Assessment of possible role of dapoxetine in premature ejaculation management. Methods: Dapoxetine, serotonin reuptake inhibitors, and premature ejaculation were all looked for in PubMed, Google scholar, and Science direct. References from relevant literature were also evaluated by the authors, but only the most recent or complete studies from February 2001 to May 2021 were included. Due to the lack of sources for translation, documents in languages other than English have been ruled out. Papers that did not fall under the purview of major scientific investigations, such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations, were omitted. Conclusion: Clinical evidence demonstrated that treatment for people with long-term or acquired PE, dapoxetine is highly effective as well as safe, and the unique properties of dapoxetine make it an appropriate choice for on-demand dosage.